Clinical Trial: DAREON™-5: A Study to Test Whether Different Doses of BI 764532 Help People With Small Cell Lung Cancer or Other Neuroendocrine Cancers
Study Status: Completed
Recruit Status: RECRUITING
Condition: Small Cell Lung Carcinoma
Study Type: INTERVENTIONAL
Official Title: DAREON™-5: An Open-label, Multi-center Phase II Dose Selection Trial of Intravenous BI 764532, a DLL3-targeting T Cell Engager, in Patients With Relapsed/Refractory Extensive-stage Small Cell Lun
Brief Summary:
This study is open to adults with small cell lung cancer and other neuroendocrine tumours.The study is in people with advanced cancer for whom previous treatment was not successful or no standard treatment exists.The purpose of this study is to find a suitable dose of BI 764532 that people with advanced cancer can tolerate when taken alone.2 different doses of BI 764532 are tested in this study.Another purpose is to check whether BI 764532 can make tumours shrink.BI 764532 is an antibody-like molecule…
Read more